<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Fertil Steril</journal-id><journal-id journal-id-type="iso-abbrev">Int J Fertil Steril</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>International Journal of Fertility &#x00026; Sterility</journal-title></journal-title-group><issn pub-type="ppub">2008-076X</issn><issn pub-type="epub">2008-0778</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25918588</article-id><article-id pub-id-type="pmc">4410033</article-id><article-id pub-id-type="other">Int-J-Fertil-Steril-9-17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Gynecology and Female Infertility</subject><subject>ART</subject></subj-group></subj-group></article-categories><title-group><article-title>A Randomized Clinical Trial on Comparing The Cycle
Characteristics of Two Different Initiation Days of
Letrozole Treatment in Clomiphene Citrate
Resistant PCOS Patients in IUI Cycles</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ghomian</surname><given-names>Nayereh</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Khosravi</surname><given-names>Ashraf</given-names></name><degrees>M.D.</degrees></contrib><contrib contrib-type="author"><name><surname>Mousavifar</surname><given-names>Nezhat</given-names></name><degrees>M.D.</degrees><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff>Ovulation Dysfunction Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</aff></contrib-group><author-notes><corresp id="cor1"><label>* Corresponding Address:</label><addr-line>P.O. Box: 9137913316</addr-line><addr-line>Ovulation Dysfunction Research Center</addr-line><addr-line>Faculty of Medicine</addr-line><institution>Mashhad University
of Medical Sciences</institution><addr-line>Mashhad</addr-line><country>Iran</country>
Email:<email>mosavifarn@mums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2015</year></pub-date><pub-date pub-type="epub"><day>21</day><month>4</month><year>2015</year></pub-date><volume>9</volume><issue>1</issue><fpage>17</fpage><lpage>26</lpage><history><date date-type="received"><day>8</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p></license></permissions><abstract><sec><title>Background</title><p>There are still many questions about the ideal protocol for letrozole (LTZ)
as the commonest aromatase inhibitor (AI) used in ovulation induction. The aim of this
study is to compare the ultrasonographic and hormonal characteristics of two different
initiation times of LTZ in clomiphene citrate (CC) failure patients and to study androgen
dynamics during the cycle.</p></sec><sec><title>Materials and Methods</title><p>This randomized clinical trial was done from March to November 2010 at the Mashhad IVF Center, a university based IVF center. Seventy infertile
polycystic ovarian syndrome (PCOS) patients who were refractory to at least 3 CC treatment cycles were randomly divided into two groups. Group A (n=35) receiving 5 mg
LTZ on cycle days 3-7 (CD3), and group B (n=35) receiving the same amount on cycle
days 5-9 (CD5). Hormonal profile and ultrasonographic scanning were done on cycle
day 3 and three days after completion of LTZ treatment (cycle day 10 or 12). Afterward,
5,000-10,000 IU human chorionic gonadotropin (hCG) was injected if at least one follicle &#x02265;18 mm was seen in ultrasonographic scanning. Intrauterine insemination (IUI) has
been done 36-40 hours later. The cycle characteristics, the ovulation and pregnancy rate
were compared between two groups. The statistical analysis was done using Fisher&#x02019;s
exact test, t test, logistic regression, and Mann-Whitney U test.</p></sec><sec><title>Results</title><p>There were no significant differences between two groups considering patient characteristics. The ovulation rate (48.6 vs. 32.4% in group A and B, respectively), the endometrial thickness, the number of mature follicles, and length of
follicular phase were not significantly different between the two groups.</p></sec><sec><title>Conclusion</title><p>LTZ is an effective treatment in CC failure PCOS patients. There are no
significant differences regarding ovulation and pregnancy rates between two different protocols of LTZ starting on days 3 and 5 of menstrual cycle (Registration Number:
IRCT201307096467N3).</p></sec></abstract><kwd-group><kwd>Letrozole</kwd><kwd>Clomiphene Citrate</kwd><kwd>Polycystic Ovarian Syndrome (PCOS)</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Ghomian N, Khosravi A, Mousavifar N. A randomized clinical trial on comparing the cycle characteristics
of two different initiation days of letrozole treatment in clomiphene citrate resistant PCOS patients in IUI cycles. Int J
Fertil Steril. 2015; 9(1): 17-26.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Clomiphene citrate (CC) is known as one of the
oldest drugs that has remained the standard choice
for ovulation induction (<xref rid="B1" ref-type="bibr">1</xref>). CC has been an appropriate,
non-expensive, and highly effective agent
for inducing ovulation since 1963 (<xref rid="B2" ref-type="bibr">2</xref>). However,
it certainly has not been successful in all patients;
about 15-20% of women do not ovulate on CC,
labeled as CC-resistant group (<xref rid="B3" ref-type="bibr">3</xref>). There are also
other problems reported about CC, such as the anti-estrogenic mucosal and endometrial changes (<xref rid="B2" ref-type="bibr">2</xref>)
that lead to higher rate of abortion and miscarriage
in ovulatory women (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>).</p><p>Letrozole (LTZ), the prominent drug in the aromatase
inhibitor (AI) family, has been introduced
as a new choice for ovulation induction in the past
decade, especially in polycystic ovarian syndrome
(PCOS) patients who have failed to respond to CC.
LTZ also seems to be very efficient in pregnancy
rates, equivalent to injectable gonadotropins, at
lower cost and with fewer adverse effects (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Furthermore, there are extra advantages for
LTZ-therapy in comparison to CC, including:
normal negative feedback mechanism for follicle-
stimulating hormone (FSH) in the brain,
more mono-follicular cycles, no negative antiestrogenic
effects on the endometrial and cervical
mucus, lower risk of ovarian hyperstimulation
syndrome (OHSS), and lesser need for
cycle monitoring (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>By reviewing the literature, we found 2000 articles
published related to CC since 1963, whereas,
there is only about 200 articles published related to
LTZ since 2000 (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>Since LTZ is a new agent in the era of ovulation
induction, there are several questions regarding
the best protocol for administering. The usual
doses for LTZ are mentioned as 2.5 and 5 mg.
Doses higher than 5 mg per day for 5 days may
result in persistence of aromatase inhibition that
is followed by low estrogen level for normal endometrial
development by the time of ovulation.
Some researchers have suggested different LTZ
protocols as follows: single dose of 20 mg given
on cycle day 3, extended dose for up to 7-10 days,
and step-up protocol including an escalating dose
of 2.5 mg on day 3 along with 10 mg on day 6. The
suggested starting day of LTZ administration is on
cycle days 3-7 (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Hormonal profile of LTZ cycles in infertility literature
is a nowadays matter of challenge. It has
been shown that LTZ can induce a marked decrease
in plasma concentrations of estradiol (E<sub>2</sub>)
and estrone, with approximately no effect on other
steroidal hormones. No accumulation of androgens,
androgen precursors, luteinizing hormone
(LH), FSH, thyroid-stimulating hormone (TSH) or
renin was reported in pharmacodynamics studies
of LTZ (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B8" ref-type="bibr">8</xref>).</p><p>On the other hand, Garcia-Velasco et al. (<xref rid="B9" ref-type="bibr">9</xref>) in
2005 found significantly elevated follicular fluid
levels of testosterone and androstenedione with
LTZ therapy during ovarian stimulation for <italic>in vitro</italic>
fertilization (IVF). Another study has reported significant
higher LH, testosterone, androstenedione,
and postovulatory progesterone (P) levels in LTZ
treated patients compared to natural cycles (<xref rid="B10" ref-type="bibr">10</xref>).
Also, in another research, some minor changes
have been found in follicular phase hormonal profiles
(P, LH, and E<sub>2</sub>) compared to natural cycles
(<xref rid="B11" ref-type="bibr">11</xref>).</p><p>It seems that there are many unknown aspects of
using aromatase inhibitors for ovulation induction.
Thus, it is reasonable to do more studies. The aims
of our study were to evaluate the cycle characteristics,
including: follicular phase length, endometrial
thickness, monofollicular response, and pregnancy
rate, of LTZ in CC failure PCOS patients in
order to compare fixed dose of LTZ between cycle
days 3 and 5 and to evaluate the hormonal changes
during these two protocols.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>Based on Rotterdam criteria, 70 PCOS patients
were enrolled in this randomized clinical trial. A
written informed consent was taken from all women
participating in this study. The diagnosis of
PCOS was made when two of the following three
criteria existed: oligomenorrhea or amenorrhea,
clinical hyperandrogenism, and polycystic ovaries
on ultrasonography. The inclusion criteria were as
follows: i. Previous diagnosis of PCOS according
to Rotterdam criteria, ii. Age between 20-30 years,
iii. No previous history of ovarian surgery and iv.
lack of ovulation with CC in at least 3 previous cycles
(lack of follicle &#x02265;18 mm on ultrasound scan).
The exclusion criteria were as follows: i. No other
infertility factors, ii. Exposure to cytotoxic drugs
and iii. Pelvic radiation therapy. The study was
performed from March to November 2010 at the
Mashhad IVF center, a university based infertility
center.</p><p>The patient&#x02019;s age, her partner&#x02019;s age, duration of
infertility, type of infertility (primary and secondary),
history of previous intrauterine insemination
(IUI) cycles, pattern of ovary (PCO and non-PCO),
pattern of menstruation (regular, oligo-menorrhea
and amenorrhea), body mass index (BMI) and basal
LH/FSH ratio were recorded for each patient.</p><p>The patients were randomly assigned into
two groups: Group A (n=35) receiving 5 mg
LTZ (Letrofem; Iran Hormone, Iran) on cycle
days 3-7 (CD3), and group B (n=35) receiving
the same amount on cycle days 5-9 (CD5)
(<xref ref-type="fig" rid="F1">Fig .1</xref>).</p><fig id="F1" orientation="portrait" position="float"><label>Fig.1</label><caption><p>PCOS; Polycystic ovary syndrome, CC; Clomiphene citrate, E<sub>2</sub>; Estradiol , LTZ; Letrozole, hCG; Human chorionic gonadotropin and
IUI; Intrauterine insemination.</p></caption><graphic xlink:href="Int-J-Fertil-Steril-9-17-g01"/></fig><p>Both groups underwent a vaginal ultrasonographic
(US) scan (probe 7.5 MHz; Ultrasonix,
USA) and a blood analysis just before the first dose
of LTZ and three days after the last dose of LTZ
therapy. US scanning were continued if indicated.</p><p>By observing at least one follicle &#x02265;18 mm,
the patient was considered ovulatory and 5,000
-10,000 IU human chorionic gonadotropin (hCG)
was injected followed by a single IUI 36-40 hours
later. Pregnancy was documented by observing fetal
pole 2 weeks after missed period.</p><p>The number of follicles .18 mm and the endometrial
thickness were measured on US scanning.
The length of follicular phase and the hormonal
levels of LH, E<sub>2</sub>, testosterone, and androstendione
were registered for all the patients before and three
days after completion of LTZ.</p><p>We used t test, chi-square, Fisher&#x02019;s exact test,
and Mann-Whitney U test by SPSS (SPSS Inc.,
Chicago, IL, USA) version 12.0 for statistical
analysis. A p value less than 0.05 was considered
significant. A comparison was done between demographic
characteristics in ovulatory (n=28) and
anovulatory patients (n=41). Follicle numbers,
endometrial thickness, follicular phase length and
pregnancy rate were compared between CD3 and
CD5 patients. The hormonal levels were compared
between two groups before and after receiving
LTZ. The hormonal levels were compared in
ovulatory and anovulatory patients before and after
treatment. This study was approved by Ethical
Committee of Mashhad University of Medical Sciences.</p></sec><sec sec-type="results"><title>Results</title><p>The total number of recruited PCOS patient in
this study was 70 (n=35/each group). There was
no significant difference between two therapeutic
groups considering patient&#x02019;s characteristics,
like: age, duration of infertility, pattern of ovary,
BMI, and basal LH/ FSH ratio (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p>The ovulation rate (presence of at least 1 follicle
&#x02265;18 mm during ovarian stimulation) in CD3
and CD5 groups were 48.6% (17/35) versus 32.4%
(11/35), respectively, whereas the difference was
not statistically significant (p=0.17).</p><p>The age, duration of infertility, pattern of ovary,
BMI, and basal LH/FSH ratio were not statistically
significant difference between ovulatory and anovulatory
patients (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>By comparing the basal androgen level, we
found that the patients with a successful ovulation
as compared to anovulatory patients had a significant
lower androstenedione (94.76&#x000b1;59.42 vs.
181.95&#x000b1;239.58 ng/dl, p=0.02) and testosterone
(33.76&#x000b1;13.26 vs. 42.10&#x000b1;18.90 ng/dl, p=0.02)
levels before treatment (<xref ref-type="table" rid="T3">Table 3</xref>).</p><p>The E<sub>2</sub> concentration was similar between
ovulatory and anovulatory patients before the
treatment (56.66&#x000b1;29.02 vs. 65.54&#x000b1;26.93 pg/
ml, respectively, p=0.32), but it was significantly
higher in ovulatory patients after treatment
(118.35&#x000b1;72.89 vs. 56.18&#x000b1;46.13 pg/ml respectively,
p=0.01, <xref ref-type="table" rid="T3">Table 3</xref>).</p><p>There was no significant difference between two
therapeutic protocols regarding the cycle characteristics.
Thus, follicular phase length (14.1&#x000b1;3.8
in CD3 and 14.7&#x000b1;1 days in CD5 patients), endometrial
thickness (8.0&#x000b1;1.16 mm in CD3 and
7.8&#x000b1;1.3 mm in CD5 patients) and mono-follicular
response (76% in CD3 and 82% in CD5 patients)
were similar between groups (p&#x0003e;0.05, <xref ref-type="table" rid="T4">Table 4</xref>).</p><p>Between two groups, testosterone significantly
increased during the treatment (36.55&#x000b1;34.55 ng/dl
for CD3 and 24.71&#x000b1;28.20 ng/dl for CD5, p&#x0003c;0.01
for both). Although this increase was higher in
CD3 patients, there is no statistically significant
difference between two groups (p=0.15, <xref ref-type="table" rid="T5">Table 5</xref>).</p><p>Androstenedione was also increased during
treatment course (75.72&#x000b1;151.92 ng/ml for CD3
and 119.50&#x000b1;116.27 ng/dl for CD5, p=0.01 for
both). Although this increase was higher in CD5
patients, there is no statistically significant difference
between two groups (p=0.21, <xref ref-type="table" rid="T5">Table 5</xref>).</p><p>The E<sub>2</sub> pattern was different between the groups.
Although there was a significant increase in the
CD3 patients, (the change from baseline=31.24 &#x000b1;
75.05 pg/ml, p=0.03), there was a decrease among
the CD5 (the change from baseline=-8.96&#x000b1;42.64
pg/ml, p=0.24). So, E<sub>2</sub> changes in two protocols
showed statistically significant difference (p=0.01,
<xref ref-type="table" rid="T5">Table 5</xref>).</p><p>The positive clinical pregnancy outcome was
also higher in CD3 patients (12.1% in CD3 versus
9.4% in CD5 patients), but the difference was not
statistically significant (p~1, <xref ref-type="table" rid="T6">Table 6</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Basic and demographic characteristics in study groups</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><th align="left" valign="top" rowspan="2" colspan="1">Variable</th><th rowspan="1" colspan="1"/><th align="left" valign="top" colspan="2" rowspan="1">Treatment group</th><th align="left" valign="top" rowspan="2" colspan="1">P value</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">CD3</th><th align="left" valign="top" rowspan="1" colspan="1">CD5</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Age (Y)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">25.3&#x000b1; 4.4</td><td rowspan="1" colspan="1">25.6&#x000b1; 3.5</td><td rowspan="1" colspan="1">0.777</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>BMI (kg/m<sup>2</sup>)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">27.0&#x000b1; 3.8</td><td rowspan="1" colspan="1">26.4&#x000b1; 4.81</td><td rowspan="1" colspan="1">0.674</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>Types of infertility</bold></td><td rowspan="1" colspan="1">Primary</td><td rowspan="1" colspan="1">31 (91.2%)</td><td rowspan="1" colspan="1">34 (97.1%)</td><td rowspan="1" colspan="1">0.356</td></tr><tr><td rowspan="1" colspan="1">Secondary</td><td rowspan="1" colspan="1">3 (8.8%)</td><td rowspan="1" colspan="1">1 (2.9%)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>Pattern of ovary</bold></td><td rowspan="1" colspan="1">PCOS</td><td rowspan="1" colspan="1">24 (68.6%)</td><td rowspan="1" colspan="1">23 (65.7%)</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">non-PCOS</td><td rowspan="1" colspan="1">11 (31.4%)</td><td rowspan="1" colspan="1">12 (34.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>Familial history of PCOS</bold></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">1 (2.9%)</td><td rowspan="1" colspan="1">3 (8.6%)</td><td rowspan="1" colspan="1">0.614</td></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">34 (97.1%)</td><td rowspan="1" colspan="1">32 (91.4%)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>LH /FSH (mIU/ml)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.35&#x000b1; 2.43</td><td rowspan="1" colspan="1">1.94&#x000b1; 1.91</td><td rowspan="1" colspan="1">0.082</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>TSH (&#x003bc;u/ml)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2.95&#x000b1; 3.03</td><td rowspan="1" colspan="1">3.29&#x000b1; 4.17</td><td rowspan="1" colspan="1">0.376<sup>a</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>PRL (ng/ml)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">24.5&#x000b1; 41.38</td><td rowspan="1" colspan="1">29.2&#x000b1; 65.43</td><td rowspan="1" colspan="1">0.672<sup>a</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>The number of previous treatment cycles</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.09&#x000b1; 0.39</td><td rowspan="1" colspan="1">1.25&#x000b1; 0.52</td><td rowspan="1" colspan="1">0.096<sup>a</sup></td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>CD3; Cycle day 3, CD5; Cycle day 5, BMI; Body mass index, PCOS; Polycystic ovary syndrome, LH; Luteinizing hormone, FSH; Folliclestimulating
hormone, TSH; Thyroid-stimulating hormone, PRL; Prolactin and a; Mann-Whitney U test results.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Basic and demographic characteristics in ovulatory and non-ovulatory patients</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><th align="left" valign="top" rowspan="3" colspan="1">Variable</th><th rowspan="1" colspan="1"/><th colspan="2" rowspan="1">Treatment group</th><th align="left" valign="top" rowspan="2" colspan="1">P value</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Ovulatoty N=28</th><th align="left" valign="top" rowspan="1" colspan="1">Anovulatory N=41</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Age (Y)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">25.40&#x000b1;3.4</td><td rowspan="1" colspan="1">23.75&#x000b1;0.54</td><td rowspan="1" colspan="1">0.971</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>BMI (kg/m<sup>2</sup>)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">26.51&#x000b1;4.61</td><td rowspan="1" colspan="1">26.76&#x000b1;4.34</td><td rowspan="1" colspan="1">0.870</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>Types of infertility</bold></td><td rowspan="1" colspan="1">Primary</td><td rowspan="1" colspan="1">28 (100%)</td><td rowspan="1" colspan="1">37 (90.5%)</td><td rowspan="1" colspan="1">0.303</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Secondary</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">4 (9.5%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>PCO pattern in ovary by ultrasonography</bold></td><td rowspan="1" colspan="1">PCOS</td><td rowspan="1" colspan="1">20 (71.0%)</td><td rowspan="1" colspan="1">32 (78.0%)</td><td rowspan="1" colspan="1">0.600</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">non-PCOS</td><td rowspan="1" colspan="1">8 (29.0%)</td><td rowspan="1" colspan="1">9 (22.0%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>Familial history of PCOS</bold></td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">1 (4.0%)</td><td rowspan="1" colspan="1">2 (5.0%)</td><td rowspan="1" colspan="1">0.303</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">27 (96.0%)</td><td rowspan="1" colspan="1">39 (95.0%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>LH (mIU/ml)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">10.17&#x000b1;7.37</td><td rowspan="1" colspan="1">10.30&#x000b1;6.49</td><td rowspan="1" colspan="1">0.942</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>FSH (mIU/ml)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7.18&#x000b1;3.62</td><td rowspan="1" colspan="1">6.28&#x000b1;2.73</td><td rowspan="1" colspan="1">0.267</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="3" colspan="1"><bold>Menstrual pattern(n)</bold></td><td rowspan="1" colspan="1">Oligo-menorrhea</td><td rowspan="1" colspan="1">25 (90.5%)</td><td rowspan="1" colspan="1">28 (72.3%)</td><td rowspan="1" colspan="1">0.096</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">Amenorrhea</td><td align="left" valign="top" rowspan="2" colspan="1">3 (9.5%)</td><td align="left" valign="top" rowspan="2" colspan="1">13 (27.7%)</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>BMI; Body mass index, PCOS; Polycystic ovary syndrome, LH; Luteinizing hormone and FSH; Follicle-stimulating hormone.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison of follicular phase testosterone, androstendione, and estradiol dynamics in CD3 and CD5 patients, before and after treatment</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Hormone</th><th align="left" valign="top" rowspan="1" colspan="1">Blood sample</th><th align="left" valign="top" rowspan="1" colspan="1">Ovulatory</th><th align="left" valign="top" rowspan="1" colspan="1">Anovulatory</th><th align="left" valign="top" rowspan="1" colspan="1">P value</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Testosterone (ng/dl)</bold></td><td rowspan="1" colspan="1">Before treatment</td><td rowspan="1" colspan="1">33.76&#x000b1;13.26</td><td rowspan="1" colspan="1">42.10&#x000b1;18.90</td><td rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">After treatment</td><td rowspan="1" colspan="1">63.41&#x000b1;30.22</td><td rowspan="1" colspan="1">69.29&#x000b1;37.15</td><td rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Androstendione (ng/dl)</bold></td><td rowspan="1" colspan="1">Before treatment</td><td rowspan="1" colspan="1">94.76&#x000b1;59.42</td><td rowspan="1" colspan="1">181.95&#x000b1;239.58</td><td rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">After treatment</td><td rowspan="1" colspan="1">176.35&#x000b1;90.92</td><td rowspan="1" colspan="1">289.159&#x000b1;207.78</td><td rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Estradiol (pg/ml)</bold></td><td rowspan="1" colspan="1">Before treatment</td><td rowspan="1" colspan="1">56.66&#x000b1;29.02</td><td rowspan="1" colspan="1">65.54&#x000b1;26.93</td><td rowspan="1" colspan="1">0.32</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">After treatment</td><td rowspan="1" colspan="1">118.35&#x000b1;72.89</td><td rowspan="1" colspan="1">56.18&#x000b1;46.13</td><td rowspan="1" colspan="1">0.01</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>CD3; Cycle day 3 and CD5; Cycle day 5.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of some cycle parameters in CD3 and CD5 patients</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Cycle characteristics</th><th align="left" valign="top" rowspan="1" colspan="1">CD3</th><th align="left" valign="top" rowspan="1" colspan="1">CD5</th><th align="left" valign="top" rowspan="1" colspan="1">P value</th></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Follicular phase length (day)</bold></td><td rowspan="1" colspan="1">14.1&#x000b1;3.8</td><td rowspan="1" colspan="1">14.7&#x000b1;1</td><td rowspan="1" colspan="1">0.093</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Endometrial thickness (mm)</bold></td><td rowspan="1" colspan="1">8.0&#x000b1;1.16</td><td rowspan="1" colspan="1">7.8&#x000b1;1.3</td><td rowspan="1" colspan="1">0.721</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Monofollicular response</bold></td><td rowspan="1" colspan="1">13 (76%)</td><td rowspan="1" colspan="1">9 (82%)</td><td rowspan="1" colspan="1">0.322</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>(among ovulatory patients)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><th colspan="4" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>CD3; Cycle day 3 and CD5; Cycle day 5.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Comparison of follicular phase testosterone, androstendione, and estradiol dynamics in CD3 and CD5 patients</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Type of hormone</th><th align="left" valign="top" rowspan="1" colspan="1">Group</th><th align="left" valign="top" rowspan="1" colspan="1">Before treatment</th><th align="left" valign="top" rowspan="1" colspan="1">After treatment</th><th align="left" valign="top" rowspan="1" colspan="1">Difference</th><th align="left" valign="top" rowspan="1" colspan="1">P value</th></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>Testosterone (ng/dl)</bold></td><td rowspan="1" colspan="1">CD3</td><td rowspan="1" colspan="1">36.00&#x000b1;15.49</td><td rowspan="1" colspan="1">72.55&#x000b1;35.94</td><td rowspan="1" colspan="1">36.55&#x000b1; 34.55</td><td rowspan="1" colspan="1">0.147</td></tr><tr><td rowspan="1" colspan="1">CD5</td><td rowspan="1" colspan="1">43.87&#x000b1;24.10</td><td rowspan="1" colspan="1">68.59&#x000b1;39.88</td><td rowspan="1" colspan="1">24.71&#x000b1; 28.20</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>Androstendione (ng/dl)</bold></td><td rowspan="1" colspan="1">CD3</td><td rowspan="1" colspan="1">153.24&#x000b1;176.29</td><td rowspan="1" colspan="1">228.96&#x000b1;116.63</td><td rowspan="1" colspan="1">75.72&#x000b1; 151.92</td><td rowspan="1" colspan="1">0.209</td></tr><tr><td rowspan="1" colspan="1">CD5</td><td rowspan="1" colspan="1">169.78&#x000b1;244.52</td><td rowspan="1" colspan="1">289.28&#x000b1;232.78</td><td rowspan="1" colspan="1">119.50&#x000b1;116.27</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1"><bold>Estradiol (pg/ml)</bold></td><td rowspan="1" colspan="1">CD3</td><td rowspan="1" colspan="1">64.00&#x000b1;29.36</td><td rowspan="1" colspan="1">95.24&#x000b1;76.94</td><td rowspan="1" colspan="1">31.24&#x000b1; 75.05</td><td rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="1" colspan="1">CD5</td><td rowspan="1" colspan="1">64.03&#x000b1;25.55</td><td rowspan="1" colspan="1">55.06&#x000b1;31.96</td><td rowspan="1" colspan="1">-8.96&#x000b1;42.64</td><td rowspan="1" colspan="1"/></tr><tr><th colspan="6" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>CD3; Cycle day 3 and CD5; Cycle day 5.</p><p>P values were calculated for the differences in hormonal values between CD3 and CD5.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Comparison of cycle outcome in CD3 and CD5 groups</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">CD3</th><th align="left" valign="top" rowspan="1" colspan="1">CD5</th><th align="left" valign="top" rowspan="1" colspan="1">P value</th></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Ovulation rate (at least one follicle more than 18 mm)</bold></td><td rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">17 (48.6%)</td><td rowspan="1" colspan="1">11 (32.4%)</td><td rowspan="1" colspan="1">0.174</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Clinical pregnancy</bold></td><td rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">4 (12.1%)</td><td rowspan="1" colspan="1">3 (9.4%)</td><td rowspan="1" colspan="1">1</td></tr><tr><th colspan="5" rowspan="1"><hr/></th></tr></tbody></table><table-wrap-foot><fn><p>CD3; Cycle day 3 and CD5; Cycle day 5.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>In two different protocols of LTZ starting on
cycle days 3 and 5, there were no significant
differences in follicular phase length, endometrial
thickness, monofollicular response, and
pregnancy rate.</p><p>AIs were originally developed for the treatment
of advanced breast cancer (<xref rid="B12" ref-type="bibr">12</xref>); however,
it has been also introduced as reproductive medicine
by Mitwally and Casper (<xref rid="B7" ref-type="bibr">7</xref>). They showed
that LTZ was effective in inducing ovulation in
women with PCOS. LTZ is rapidly and completely
absorbed from gastrointestinal (GI) tract
with absolute bioavailability of 99.9%. The terminal
elimination half-life in plasma is about 2
days and the maximal suppression of estrogen
concentration is achieved in 48-78 hours after
single oral dose administration.</p><p>Since only a decade has passed since the introduction
of LTZ in the field of ovarian stimulation,
there is still debate about the optimal
protocol to use. The dosage of LTZ, therefore,
differs between studies. The majority of researchers
have used 2.5-5.0 mg LTZ daily based
on the dosage used for the treatment of patients
with breast cancer (<xref rid="B12" ref-type="bibr">12</xref>). In one study, the effect
of a single dose of 20 mg LTZ on cycle day
3 was compared to 2.5 mg on cycle days 3-7,
which was not significantly different in pregnancy
rate (<xref rid="B13" ref-type="bibr">13</xref>). In another study, 7.5 mg LTZ
for 5 days was compared to 150 mg CC that was
proved to be more efficacious in terms of ovulation
and pregnancy rates (<xref rid="B14" ref-type="bibr">14</xref>).</p><p>The duration of stimulation in most studies was
similar to CC, namely 5 days in the early follicular
phase, although longer stimulation for 10 days has
been also tested (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>To induce ovulation, FSH is necessary in the
early phase of the cycle to recruit and to select
follicles. In ovulation cycles by gonadotropins,
the earlier time for FSH administration is started
during the cycles (prior to the selection phase) and
more follicles are then recruited (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>CC is usually administered on day 5 of menstruation.
This is based on the theory that on
cycle day 5, a physiologic decrease in FSH concentration
provides the means for selection of
the dominant follicle. Initiation of the drug on
cycle day 2 induces earlier ovulation which is
analogous to the physiologic events of the normal
menstrual cycle. In one study, ovulation and
conception rates and pregnancy outcome were
similar when CC treatment started anywhere
between cycle days 2 and 5 (<xref rid="B16" ref-type="bibr">16</xref>). In another
study, CC was started on cycle days 3, 4, 5, or
7 in IVF cycles. The researchers concluded that
protocol of cycle day 5 had more oocytes recovered,
fertilized and transferred (<xref rid="B17" ref-type="bibr">17</xref>). In another
study, CC commenced on day 1 of the menstrual
cycle rather than day 5 resulted in more rapid
follicular growth and higher pregnancy rate in
IUI cycles (<xref rid="B18" ref-type="bibr">18</xref>). Treatment with CC was associated
with higher rate of pregnancy if started
early (days 1 through 5 than 5 through 9) in the
menstrual cycle in the study by Dehbashi et al.
(<xref rid="B19" ref-type="bibr">19</xref>).</p><p>Based on experiences on CC, the starting day
for LTZ in most studies has been found on day 3
of spontaneous or induced menstruation. In one study, 5 mg LTZ administered on cycle days
1-10 showed higher pregnancy rate compared
to same amount administered from cycle days
1-5 (<xref rid="B1" ref-type="bibr">1</xref>). In another study, they compared the effect
of 2.5 mg LTZ administered on cycle days
2-6 to placebo and their findings showed 33.3%
ovulation rate compared to 0.00% for the placebo
(<xref rid="B20" ref-type="bibr">20</xref>).</p><p>In our study, we compared the cycle characteristics
for two different starting days including
cycle days 5 and 3 in CC resistant PCOS patients
who developed no dominant follicle during their
previous cycles with CC, examined by ultrasound
scanning. Our findings did not show significant
difference in ovulation rate between CD3 and CD5
groups. The overall ovulation rate was 40.6%. The
monofollicular response showed no significant differences
between two groups. In different studies,
this rate has been reported between 33.3%
(<xref rid="B20" ref-type="bibr">20</xref>) to 84.4% (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>In our study, the endometrial thickness was
not significantly different between CD3 and
CD5 groups. The overall endometrial thickness
in both groups was 7.9 mm compared to 11.2
mm in a study by Bedaiwy et al. (<xref rid="B11" ref-type="bibr">11</xref>) and 7.1
mm in a study by Al-Fozan et al. (<xref rid="B14" ref-type="bibr">14</xref>).</p><p>There was 4 (12.1%) clinical pregnancies in
CD3 group and 3 (9.4%) in CD5 group. The total
pregnancy rate was 10.8%. The pregnancy rate in
cycles of LTZ treatment in literature is 5.6% (<xref rid="B20" ref-type="bibr">20</xref>)
to 40.6% 9 (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>In our research, we studied the hormonal dynamics
as well. In both groups, testosterone and androstenedione
concentrations were increased from
baseline three days after termination of LTZ treatment.
The change from baseline was 30.5 ng/dl for
testosterone and 98.7 ng/dl for androstenedione. It
could be realized that the patients with lower serum
androgens level would get more benefit from
LTZ treatment.</p><p>Serum E<sub>2</sub> concentration was increased from
baseline for 31.2 pg/ml in CD3 group and decreased
for 8.96 pg/ml in CD5 group. This difference
should be related to E<sub>2</sub> secretion from
the ovum.</p><p>Reviewing the pharmacokinetic studies of
LTZ, there was no effect on plasma concentration
of testosterone and androstenedione after
single doses of 0.1-5 mg (<xref rid="B8" ref-type="bibr">8</xref>). On the other hand,
Garcia-Velasco et al. (<xref rid="B9" ref-type="bibr">9</xref>) have shown a significant
increase in intrafollicular androgen levels
in IVF cycles treated by LTZ. Cortinez et al.
(<xref rid="B10" ref-type="bibr">10</xref>) have also shown an increase in serum androgen
level and a decrease in E<sub>2</sub> levels on the
last day of LTZ treatment compared to natural
cycle.</p><p>In our study, the androgen levels were increased
significantly 3 days after termination of
LTZ, days 10 and 12 for CD3 and CD5 groups,
respectively. The follicular phase length was
shown in both groups for about 14 days, and
high androgen level at the time of conception
was also considered.</p><p>PCOS patients experience a higher incidence
of miscarriage, preterm delivery and low birth
weight infants (<xref rid="B23" ref-type="bibr">23</xref>) that has been attributed to
hyperandrogenic state of this syndrome, indicated
by many authors (<xref rid="B24" ref-type="bibr">24</xref>-<xref rid="B26" ref-type="bibr">26</xref>). The other effect
of hyperandrogenism in PCOS pregnant
patients at the early embryonic stage has been
proposed as a developmental etiology for PCOS
in female fetus (<xref rid="B27" ref-type="bibr">27</xref>).</p><p>Therefore, it seems logical that an increase in
androgen level after receiving LTZ in hyperandrogenic
PCOS patients at the time of conception
should become a major concern.</p><p>Although we have not measured free androgen
index (FAI) in our patients, but our finding showed
that anovulatory patients in both groups had significantly
higher basal androgen levels and this was
in accordance with Imani et al. (<xref rid="B28" ref-type="bibr">28</xref>), in which they
proved FAI as an important predictor of ovulation
in CC protocol.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>LTZ is an alternative treatment in PCOS patients.
Two different protocols of LTZ starting
on cycle days 3 and 5 showed no significant differences
in follicular phase length, endometrial
thickness, monofollicular response, and pregnancy
rate. Androgen levels were significantly
increased after treatment. Lower basal androgen
levels showed significantly better result.
More studies are needed to evaluate different
initiation day, length, and dose for LTZ administration.</p></sec></body><back><ack><p>The study was the result of a thesis presented for
the specialty degree in Obstetrics &#x00026; Gynecology,
number 2327-T. The authors would like to thank
to Mashhad University of Medical Sciences for financial
support. There was no conflict of interest
in this article.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badawy</surname><given-names>A</given-names></name><name><surname>Mosbah</surname><given-names>A</given-names></name><name><surname>Tharwat</surname><given-names>A</given-names></name><name><surname>Eid</surname><given-names>M</given-names></name></person-group><article-title>Extended letrozole therapy for ovulation induction in clomipheneresistant women with polycystic ovary syndrome: a novel protocol</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><issue>1</issue><fpage>236</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">18706549</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casper</surname><given-names>RF</given-names></name><name><surname>Mitwally</surname><given-names>MF</given-names></name></person-group><article-title>Review: aromatase inhibitors for ovulation induction</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><issue>3</issue><fpage>760</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">16384846</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franks</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Mason</surname><given-names>H</given-names></name><name><surname>Polson</surname><given-names>D</given-names></name></person-group><article-title>Ovulatory disorders in women with polycystic ovary syndrome</article-title><source>Clin Obstet Gynaecol</source><year>1985</year><volume>12</volume><issue>3</issue><fpage>605</fpage><lpage>632</lpage><pub-id pub-id-type="pmid">3933879</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatnagar</surname><given-names>AS</given-names></name><name><surname>Hausler</surname><given-names>A</given-names></name><name><surname>Schieweck</surname><given-names>K</given-names></name><name><surname>Lang</surname><given-names>M</given-names></name><name><surname>Bowman</surname><given-names>R</given-names></name></person-group><article-title>Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor</article-title><source>J Steroid Biochem Mol Biol</source><year>1990</year><volume>37</volume><issue>6</issue><fpage>1021</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">2149502</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polyzos</surname><given-names>NP</given-names></name><name><surname>Tzioras</surname><given-names>S</given-names></name><name><surname>Badawy</surname><given-names>AM</given-names></name><name><surname>Valachis</surname><given-names>A</given-names></name><name><surname>Dritsas</surname><given-names>C</given-names></name><name><surname>Mauri</surname><given-names>D</given-names></name></person-group><article-title>Aromatase inhibitors for female infertility: a systematic review of the literature</article-title><source>Reprod Biomed Online</source><year>2009</year><volume>19</volume><issue>4</issue><fpage>456</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">19909585</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casper</surname><given-names>RF</given-names></name><name><surname>Mitwally</surname><given-names>MF</given-names></name></person-group><article-title>Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome</article-title><source>Clin Obstet Gynecol</source><year>2011</year><volume>54</volume><issue>4</issue><fpage>685</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">22031258</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitwally</surname><given-names>MF</given-names></name><name><surname>Casper</surname><given-names>RF</given-names></name></person-group><article-title>Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovary syndrome</article-title><source>Reproductive Technologies</source><year>2000</year><volume>10</volume><issue>5</issue><fpage>244</fpage><lpage>247</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buzdar</surname><given-names>AU</given-names></name><name><surname>Robertson</surname><given-names>JF</given-names></name><name><surname>Eiermann</surname><given-names>W</given-names></name><name><surname>Nabholtz</surname><given-names>JM</given-names></name></person-group><article-title>An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane</article-title><source>Cancer</source><year>2002</year><volume>95</volume><issue>9</issue><fpage>2006</fpage><lpage>2016</lpage><pub-id pub-id-type="pmid">12404296</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Velasco</surname><given-names>JA</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Pacheco</surname><given-names>A</given-names></name><name><surname>Guillen</surname><given-names>A</given-names></name><name><surname>Duque</surname><given-names>L</given-names></name><name><surname>Requena</surname><given-names>A</given-names></name><etal/></person-group><article-title>The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves <italic>in vitro</italic> fertilization outcome in low responder patients: a pilot study</article-title><source>Fertil Steril</source><year>2005</year><volume>84</volume><issue>1</issue><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">16009161</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortinez</surname><given-names>A</given-names></name><name><surname>De Carvalho</surname><given-names>I</given-names></name><name><surname>Vantman</surname><given-names>D</given-names></name><name><surname>Gabler</surname><given-names>F</given-names></name><name><surname>I&#x000f1;iguez</surname><given-names>G</given-names></name><name><surname>Vega</surname><given-names>M</given-names></name></person-group><article-title>Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients</article-title><source>Fertil Steril</source><year>2005</year><volume>83</volume><issue>1</issue><fpage>110</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">15652895</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bedaiwy</surname><given-names>MA</given-names></name><name><surname>Abdelaleem</surname><given-names>MA</given-names></name><name><surname>Hussein</surname><given-names>M</given-names></name><name><surname>Mousa</surname><given-names>N</given-names></name><name><surname>Brunengraber</surname><given-names>LN</given-names></name><name><surname>Casper</surname><given-names>RF</given-names></name></person-group><article-title>Hormonal, follicular and endometrial dynamics in letrozole-treated versus natural cycles in patients undergoing controlled ovarian stimulation</article-title><source>Reprod Biol Endocrinol</source><year>2011</year><volume>9</volume><fpage>83</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">21693028</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Zilembo</surname><given-names>N</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name><name><surname>Di Leo</surname><given-names>A</given-names></name><name><surname>Celio</surname><given-names>L</given-names></name><etal/></person-group><article-title>Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><issue>2</issue><fpage>208</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">10448261</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitwally</surname><given-names>MF</given-names></name><name><surname>Casper</surname><given-names>RF</given-names></name></person-group><article-title>Single-dose administration of an aromatase inhibitor for ovarian stimulation</article-title><source>Fertil Steril</source><year>2005</year><volume>83</volume><issue>1</issue><fpage>229</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">15652918</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Fozan</surname><given-names>H</given-names></name><name><surname>Al-Khadouri</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>SL</given-names></name><name><surname>Tulandi</surname><given-names>T</given-names></name></person-group><article-title>A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation</article-title><source>Fertil Steril</source><year>2004</year><volume>82</volume><issue>6</issue><fpage>1561</fpage><lpage>1563</lpage><pub-id pub-id-type="pmid">15589860</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badawy</surname><given-names>A</given-names></name><name><surname>Abdel Aal</surname><given-names>I</given-names></name><name><surname>Abulatta</surname><given-names>M</given-names></name></person-group><article-title>Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><issue>3</issue><fpage>849</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">17582406</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Winkel</surname><given-names>CA</given-names></name></person-group><article-title>The effect of therapy initiation day on clomiphene citrate therapy</article-title><source>Fertil Steril</source><year>1989</year><volume>52</volume><issue>4</issue><fpage>564</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">2806595</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrs</surname><given-names>RP</given-names></name><name><surname>Vargyas</surname><given-names>JM</given-names></name><name><surname>Shangold</surname><given-names>GM</given-names></name><name><surname>Yee</surname><given-names>B</given-names></name></person-group><article-title>The effect of time of initiation of clomiphene citrate on multiple follicle development for human <italic>in vitro</italic> fertilization and embryo replacement procedures</article-title><source>Fertil Steril</source><year>1984</year><volume>41</volume><issue>5</issue><fpage>682</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">6714446</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biljan</surname><given-names>MM</given-names></name><name><surname>Mahutte</surname><given-names>NG</given-names></name><name><surname>Tulandi</surname><given-names>T</given-names></name><name><surname>Tan</surname><given-names>SL</given-names></name></person-group><article-title>Prospective randomized double-blind trial of the correlation between time of administration and antiestrogenic effects of clomiphene citrate on reproductive end organs</article-title><source>Fertil Steril</source><year>1999</year><volume>71</volume><issue>4</issue><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">10202871</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehbashi</surname><given-names>S</given-names></name><name><surname>Vafaei</surname><given-names>H</given-names></name><name><surname>Parsanezhad</surname><given-names>MD</given-names></name><name><surname>Alborzi</surname><given-names>S</given-names></name></person-group><article-title>Time of initiation of clomiphene citrate and pregnancy rate in polycystic ovarian syndrome</article-title><source>Int J Gynaecol Obstet</source><year>2006</year><volume>93</volume><issue>1</issue><fpage>44</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">16530767</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath</surname><given-names>MS</given-names></name><name><surname>Aleyamma</surname><given-names>TK</given-names></name><name><surname>Chandy</surname><given-names>A</given-names></name><name><surname>George</surname><given-names>K</given-names></name></person-group><article-title>Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial</article-title><source>Fertil Steril</source><year>2010</year><volume>94</volume><issue>7</issue><fpage>2857</fpage><lpage>2859</lpage><pub-id pub-id-type="pmid">20638059</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Omari</surname><given-names>WR</given-names></name><name><surname>Sulaiman</surname><given-names>WR</given-names></name><name><surname>Al-Hadithi</surname><given-names>N</given-names></name></person-group><article-title>Comparison of two aromatase inhibitors in women with clomipheneresistant polycystic ovary syndrome</article-title><source>Int J Gynaecol Obstet</source><year>2004</year><volume>85</volume><issue>3</issue><fpage>289</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">15145273</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begum</surname><given-names>MR</given-names></name><name><surname>Ferdous</surname><given-names>J</given-names></name><name><surname>Begum</surname><given-names>A</given-names></name><name><surname>Quadir</surname><given-names>E</given-names></name></person-group><article-title>Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><issue>3</issue><fpage>853</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">18177867</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Spuy</surname><given-names>ZM</given-names></name><name><surname>Dyer</surname><given-names>SJ</given-names></name></person-group><article-title>The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome</article-title><source>Best Pract Res Clin Obstet Gynaecol</source><year>2004</year><volume>18</volume><issue>5</issue><fpage>755</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">15380145</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>HL</given-names></name></person-group><article-title>Extraand intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence</article-title><source>Hum Reprod Update</source><year>2011</year><volume>17</volume><issue>1</issue><fpage>17</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">20639519</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okon</surname><given-names>MA</given-names></name><name><surname>Laird</surname><given-names>SM</given-names></name><name><surname>Tuckerman</surname><given-names>EM</given-names></name><name><surname>Li</surname><given-names>TC</given-names></name></person-group><article-title>Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function</article-title><source>Fertil Steril</source><year>1998</year><volume>69</volume><issue>4</issue><fpage>682</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">9548158</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuckerman</surname><given-names>EM</given-names></name><name><surname>Okon</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Laird</surname><given-names>SM</given-names></name></person-group><article-title>Do androgens have a direct effect on endometrial function?. An in vitro study</article-title><source>Fertil Steril</source><year>2000</year><volume>74</volume><issue>4</issue><fpage>771</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">11020522</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>DH</given-names></name><name><surname>Barnett</surname><given-names>DK</given-names></name><name><surname>Bruns</surname><given-names>CM</given-names></name><name><surname>Dumesic</surname><given-names>DA</given-names></name></person-group><article-title>Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?</article-title><source>Hum Reprod Update</source><year>2005</year><volume>11</volume><issue>4</issue><fpage>357</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">15941725</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imani</surname><given-names>B</given-names></name><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>te Velde</surname><given-names>ER</given-names></name><name><surname>Habbema</surname><given-names>JD</given-names></name><name><surname>Fauser</surname><given-names>BC</given-names></name></person-group><article-title>Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><issue>5</issue><fpage>1617</fpage><lpage>1622</lpage><pub-id pub-id-type="pmid">10323389</pub-id></element-citation></ref></ref-list></back></article>